“Emerging data for PT150 and PT157 show promising results in ex-plant models for pancreatic cancer, glioblastoma and treatment-resistant prostate cancer”
ASCO20 Scientific Program Abstract
PT150
A new modulator of glucocorticoid and androgen receptors with antiviral activity against SARS-CoV-2
PT150
A novel glucocorticoid and androgen receptor modulator reduces viral entry and innate immune inflammatory responses in the Syrian Hamster model of SARS-CoV-2
PT Oncology Drug Platform
Glucocorticoid & Androgen Receptor Antagonist/Modulators for Oncology
National Cancer Institute Study Results on Multiple Cancers
PT150 Oncology Studies
PT157 Oncology Studies
PT162 Oncology Studies
PT167 Oncology Studies
Palisades Therapeutics new class of Antibiotics granted patent
The Palisades Therapeutics’ Potentiating Agents as broad-spectrum adjunctive therapeutics (Recently patented proprietary compounds as a platform).
